Aerska's AOC "brain shuttle" $39M funding validates modality, implications for Avidity Biosciences

AOC SHIFT TO CNS SIGNALS PLATFORM VALIDATION

Aerska’s recent Series A financing for its antibody‑oligonucleotide conjugate (AOC) platform is sharpening industry attention on AOC technology and its potential beyond peripheral tissues. The Amsterdam‑based financing announcement sees EQT Life Sciences’ LSP Dementia Fund and age1 back Aerska’s “brain shuttle” approach to deliver RNA interference (RNAi) therapeutics systemically across the blood–brain barrier. That shift — from targeted muscle or liver delivery to uniform deep‑brain distribution via IV or SC dosing — highlights a delivery strategy that companies such as Avidity Biosciences are watching closely.

What this means for Avidity Biosciences

Aerska’s push into central nervous system (CNS) therapeutics is offering a read‑across for Avidity Biosciences, which develops AOC therapies for neuromuscular diseases. The funding and technical focus validate the underlying AOC modality as broadly applicable to diverse tissues, reinforcing investor and partner interest in antibody‑linked oligonucleotides. For Avidity, this development underlines both opportunity and pressure: the modality’s extension into the brain could open partnership or licensing avenues while intensifying competition for talent, platform IP and industry collaborations targeting delivery solutions.

The emphasis on systemic, durable target knockdown in deep brain regions also reframes commercial and regulatory considerations for Avidity and peers. If Aerska’s brain shuttle achieves reliable blood–brain barrier crossing with acceptable safety and durability, it accelerates a narrative that AOC platforms can meet clinical and regulatory endpoints in difficult‑to‑treat organs. That outcome would broaden the addressable market for oligonucleotide therapeutics and influence trial design, safety monitoring and route‑of‑administration planning across companies pursuing AOC strategies.

ADDITIONAL FINANCING AND TECHNOLOGY DETAILS

The Series A totals USD 39 million and follows a seed round announced in October 2025, bringing Aerska’s cumulative funding to USD 60 million. EQT Life Sciences’ LSP Dementia Fund co‑leads the round with age1, joined by laso Ventures and existing investors. Aerska plans to use proceeds to advance its AOC platform toward the clinic, prioritising intravenous or subcutaneous administration designed to achieve uniform brain distribution and durable gene knockdown.

INDUSTRY QUOTES AND STRATEGIC AIMS

Aerska’s management frames systemic delivery as a route to earlier, disease‑modifying intervention in genetically driven Alzheimer’s and other neurodegenerative disorders. CEO Jack O’Meara and EQT’s Philip Scheltens underscore the potential to preserve cognitive function and broaden patient access, while the company signals intent to pursue industry partnerships to scale development and meet regulatory safety and durability expectations.